Verrica Pharmaceuticals Inc. Share Price
NASDAQ: VRCA | Micro CapVerrica Pharmaceuticals Inc. Stock Performance
Open $5.31 | Prev. Close $5.10 | Circuit Range N/A |
Day Range $5.08 - $5.54 | Year Range $3.38 - $9.58 | Volume 5,968 |
Average Traded $5.33 |
Verrica Pharmaceuticals Inc. Share Price Today
As of 29 August 2026, Verrica Pharmaceuticals Inc.'s share price is $5.77. The stock opened at $5.31, compared to its previous close of $5.10. During today's trading session, Verrica Pharmaceuticals Inc.'s share price traded between $5.08 and $5.54, with an average price of $5.31. Over the past 52 weeks, the stock has recorded a high of $9.58 and a low of $3.38. In terms of performance, Verrica Pharmaceuticals Inc.'s share price has risen by 5.48% over the last six months and is up 4.53% on a year-on-year basis.
Verrica Pharmaceuticals Inc. Share Price Chart
Verrica Pharmaceuticals Inc. Stock Fundamentals & Key Indicators
Market Cap $61.46M | PE Ratio (TTM) -3.43 | Dividend Yield N/A |
EPS (TTM) $-1.68 | Revenue (TTM) $35.58M | Return On Equity (TTM) -72.29% |
Profit Margin -50.27% | Debt to Equity 0.66 | Quarterly Earnings Growth YoY 98.80% |
Verrica Pharmaceuticals Inc. Quarterly Profit & Loss
All figures in USD
Verrica Pharmaceuticals Inc. Annual Profit & Loss
All figures in USD
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.42 | $5.00 | -6.02% |
Jul 2026 | $6.17 | $5.32 | -13.50% |
Jun 2026 | $5.90 | $6.15 | +4.24% |
May 2026 | $6.31 | $5.90 | -8.53% |
Apr 2026 | $5.55 | $6.45 | +23.09% |
Mar 2026 | $5.41 | $5.24 | -4.20% |
Feb 2026 | $7.55 | $5.47 | -22.41% |
Jan 2026 | $8.30 | $7.05 | -15.16% |
Dec 2025 | $7.99 | $8.31 | -8.38% |
Nov 2025 | $3.52 | $9.07 | +158.40% |
Oct 2025 | $4.38 | $3.51 | -17.61% |
Sep 2025 | $5.31 | $4.26 | -22.83% |
VRCA Share Price FAQs
What is Verrica Pharmaceuticals Inc. share price today?
What is the 52 week high and 52 week low of Verrica Pharmaceuticals Inc. stock?
What is VRCA's market capitalisation today?
What is VRCA's net income for the last quarter?
What is the 5 year returns of VRCA?
What is the high & low stock price of VRCA today?
Can I buy VRCA shares in India?